Fig. 44.1
An assistant applies cricoid pressure to prevent aspiration during rapid sequence intubation
Another means that could eventually screen for patients at high risk of aspiration is gastric sonography. Perlas et al. recently devised a simple, 3-point grading system (based upon two ultrasound views) that can predict a patient’s gastric residual volume prior to intubation. This information may then be used to classify patients into risk groups based on their residuals. After applying their new method, they determined that approximately 43 % of preoperative, fasted patients truly had empty stomachs, 53.5 % had small residuals (still considered safe for surgery), while 3.5 % of patients had gastric residuals beyond the recommended safe limit. Work remains to be done in developing this method, but it certainly appears to have promise for evaluating a patient’s risk of aspiration and guiding subsequent decisions.
Treatment
If pulmonary aspiration does occur, treatment includes suctioning the upper airway, considering use of a bronchoscope (if there is solid matter within the airways), and continuing to provide supportive respiration and oxygenation. Endotracheal intubation may be necessary to maintain gas exchange. Tracheal secretions should be cultured. Antibiotic decisions are often based on the culture results, and empiric antibiotics are only recommended if the patient has aspirated grossly contaminated matter. Steroids should probably not be used since they may potentiate the development of secondary pneumonia or sepsis. Additionally, neutralizing agents should not be administered.
Postoperative Nausea and Vomiting
Postoperative nausea and vomiting (PONV) is defined as nausea or vomiting occurring within 24 h after completion of surgery. The overall incidence of PONV in surgical patients who have not received prophylaxis is approximately 25–35 %, while up to 70–80 % of high-risk patients experience PONV. Postdischarge nausea and vomiting (PDNV), which is particularly relevant to patients undergoing ambulatory surgery, refers to nausea and vomiting occurring within 72 h after surgery. The incidence of PDNV has been quoted at 20–50 %, including 17 % and 8 % of patients who experience nausea and vomiting after discharge, respectively.
Avoiding nausea and vomiting after surgery is an extremely important issue for patients. In fact, patients rated nausea/vomiting as their biggest fear during the perioperative period—even above concerns of death, perioperative pain, myocardial infarction, and stroke. In addition to patient dissatisfaction and discomfort, PONV can have grave effects on patient outcomes. It is among the leading causes of unanticipated hospital admission and can lead to delays in discharge, readmissions to the hospital, compromised mobility, respiratory problems (aspiration, pneumonia, pneumothoracies), wound dehiscence (tension on suture lines), surgical bleeding, subcutaneous emphysema, and esophageal rupture among other things. PONV also leads to hundreds of millions of dollars of added healthcare expenses each year.
Risk Factors
There are a number of risk factors which predispose a patient to PONV. Identified risks include female gender, nonsmoking status (1.5–2.5 times risk), age (5 % incidence in infants, 25 % in children <5 years old, 40–50 % in 5–15 year olds, and 20–40 % in adults), history of motion sickness, history of PONV, obesity, anxiety, history of migraines, duration of surgery, use of narcotics during surgery and/or postoperatively, intraoperative use of volatile anesthetics and/or nitrous oxide, decreased administration of fluids during surgery, hypotension, and use of anticholinesterases (>2.5 mg neostigmine). Surgeries that predispose patients to PONV include laparoscopic procedures (especially gynecological), intra-abdominal surgeries, head/neck surgeries, strabismus repair, neurosurgeries, shoulder procedures, dental surgeries, and varicose vein stripping.
Recently, models have been developed that incorporate these risk factors to predict the likelihood of a patient experiencing PONV. Among such models, the Apfel score is the best known and most widely used. This model assigns one point for each of the following patient characteristics: female gender, nonsmoker, history of motion sickness or PONV, and plan to use postoperative opioids. When 0, 1, 2, 3, or 4 of the risk factors are present for a given patient, his/her risk of experiencing PONV is approximately 10 %, 20 %, 40 %, 60 %, or 80 %, respectively. The Koivuranta score and the Eberhart score (specifically for pediatric patients) have also been developed as alternative risk models. All three models have gained popularity because they are very simple and easy to apply—they all use only 4–5 risk factors to calculate a prediction score, with each factor worth exactly one point.
The Apfel, Koivuranta, and Eberhart scores, among other risk models, were developed to minimize unnecessary administration of prophylactic antiemetics. Like all medications, antiemetics have costs, side effects, and variable efficacies. Proponents of the Apfel score and other risk prediction models argue these tools are useful for determining which patients should versus should not be given antiemetic prophylaxis. The Apfel score is often applied in conjunction with recommendations from the “Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting,” and the “Consensus Guidelines for Managing Postoperative Nausea and Vomiting.” These documents recommend not providing prophylaxis to low-risk patients, giving one or two antiemetics to moderate-risk patients, and administering two or more antiemetics from different classes to those patients at highest risk of PONV. Propofol can also be used throughout the case for total intravenous anesthesia (TIVA), and this allows for one less antiemetic to be given. When applied to help guide decision making regarding prophylaxis, Apfel’s model has been shown to be efficacious and efficient in decreasing PONV in adults.
Despite this evidence, many clinicians support a more liberal use of antiemetics for preventing PONV. They strongly emphasize the low cost, benign side effects, and impressive efficacy of the available antiemetic drugs. Given the essential need to avoid PONV, it is recommended that all surgical patients be treated with at least two antiemetics. The risk factors should certainly be considered and applied to help guide decision making, but physicians should not be restricted to risk models (with inherent limitations) to predetermine their actions.
Antiemetic Therapy
Nausea is a very complex phenomenon, and it can be triggered from multiple centers—the lateral reticular formation of the medulla, chemoreceptor trigger zone (CRTZ) in the area postrema, nucleus tractus solitarius (NTS), vestibular system, higher cortical regions, cerebellum, glossopharyngeal nerve, and vagal nerve (Fig. 44.2). There are multiple receptors that contribute to the sensation of nausea, including serotonin, histamine, acetylcholine, and dopamine. This explains why such a wide variety of pharmaceuticals have shown benefit in preventing and treating nausea and vomiting (Table 44.1). It is important to note that drugs from different classes work additively (but not synergistically), and they can be combined safely as they do not usually interact with one another.
Fig. 44.2
Mechanism of nausea and vomiting
Table 44.1
Antiemetics
Class/mechanism of action | Drug | Efficacy | Side effects | Comments |
---|---|---|---|---|
Serotonin (5-HT3) antagonists | Ondansetron (Zofran), granisetron, dolasetron, tropisetron, palonosetron | All agents are equally effective • Ondansetron is equal to dexamethasone and droperidol in efficacy • Palonosetron has stronger affinity and longer half-life | • Minimal • Mild headache, constipation, dizziness • Asymptomatic QT prolongation, increased LFTs • Does not cause sedation | • Best when given near end of surgery for prophylaxis • Best agent for pediatric patients • Most effective when combined with other agents • Better antivomiting than antinausea effects
Full access? Get Clinical TreeGet Clinical Tree app for offline access |